Undisclosed DYRK inhibitor for diabetes / Biosplice Therap, Novo Nordisk - LARVOL DELTA

Biosplice Announces Collaboration with Novo Nordisk in Diabetes (GlobeNewswire) - "Biosplice Therapeutics...has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes. This agreement builds upon Biosplice’s innovative research, supported by robust external scientific literature, demonstrating the potential of DYRK inhibition to stimulate β-cell proliferation in animal models and human islet cells, thus offering a promising avenue for diabetes treatment. The collaboration combines Novo Nordisk’s expertise in diabetes and Biosplice’s research and development efforts focused on creating selective and potent DYRK inhibitors...Under the terms of the agreement, Novo Nordisk will fund further preclinical development, with an exclusive option to license Biosplice’s relevant intellectual property primarily focused on cardiometabolic disorders...Biosplice will present publicly some of its preclinical findings....at the upcoming American Diabetes Association’s conference in Orlando, Florida on June 23 at 12:30 pm."

Licensing / partnership • Preclinical • Diabetes • Metabolic Disorders